Monthly Cost Breakdown: What You'll Pay When Switching
Understanding the Switch From Mounjaro to Wegovy: Wait Times and Considerations
When switching from Mounjaro to Wegovy, most patients wonder about mandatory waiting periods between treatments. The reality is that switching from Mounjaro to Wegovy typically doesn't require a specific waiting period, as both are GLP-1-based medications with similar mechanisms. Your prescriber will assess your individual circumstances, including how long you've been on Mounjaro, your current dose, and any side effects experienced. This personalised approach ensures switching from Mounjaro to Wegovy happens safely and effectively.
The decision on where to start your Wegovy dose escalation depends on your Mounjaro experience and clinical response. Some prescribers may recommend starting Wegovy at the standard 0.25mg dose regardless of your previous Mounjaro dose, whilst others might adjust based on your tolerance. This flexibility in switching from Mounjaro to Wegovy helps minimise side effects whilst maintaining therapeutic benefits. At EverydayMeds, our clinical team works with your prescriber to ensure a smooth transition between these prescription-only medicines.
Monthly Cost Analysis: Budgeting Your Switch From Mounjaro to Wegovy
Understanding the monthly costs when switching from Mounjaro to Wegovy helps you budget effectively for your weight management journey. Wegovy follows a 16-week dose escalation schedule starting at £79.99 for the 0.25mg starter dose (weeks 1-4), progressing to £94.99 for 0.5mg (weeks 5-8), £99.99 for 1mg (weeks 9-12), and £139.99 for 1.7mg (weeks 13-16). New customers use code FIRST40 at checkout to access these prices when switching from Mounjaro to Wegovy.
The maintenance dose of 2.4mg costs £209.99 monthly from week 17 onwards, representing your long-term monthly investment when switching from Mounjaro to Wegovy. Returning customers can use code DOSE25 to maintain competitive pricing throughout their treatment. Our bundle options like the Progress Duo (0.5mg & 1mg) at £189.99 provide convenient two-month supplies, whilst the Ultimate Stability Trio offers three months of maintenance dosing at £649.99, helping you plan your monthly expenses more effectively.
Clinical Evidence Supporting Your Switch From Mounjaro to Wegovy
The clinical evidence supporting Wegovy comes from the comprehensive STEP trial programme, demonstrating its effectiveness as a prescription-only medicine for weight management. In the pivotal STEP 1 trial (Wilding et al., NEJM, 2021), patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo. The STEP 5 trial showed sustained weight loss of approximately 15.2% at two years, supporting long-term effectiveness when switching from Mounjaro to Wegovy.
Recent SELECT cardiovascular outcomes data revealed a 20% reduction in major cardiovascular events (hazard ratio 0.80), providing additional clinical rationale for some patients considering switching from Mounjaro to Wegovy. However, both medications have demonstrated clinical efficacy in their respective trials, and the decision to switch should be made with your prescriber based on individual clinical factors, tolerance, and treatment goals.
How Wegovy Works: Mechanism When Switching From Mounjaro to Wegovy
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to support weight management alongside a reduced-calorie diet and increased physical activity. When switching from Mounjaro to Wegovy, you're moving from a dual GIP/GLP-1 receptor agonist to a selective GLP-1 agonist, which may result in different effects on appetite regulation and satiety. Wegovy works by reducing appetite, promoting feelings of fullness after smaller meals, and may help reduce food cravings by acting on brain appetite centres. The once-weekly injection using the FlexTouch pen delivers consistent medication levels, supporting your weight management goals throughout the week. This mechanism makes switching from Mounjaro to Wegovy a clinically sound option for many patients seeking continued pharmaceutical support for weight management.
Ordering Process: Getting Started When Switching From Mounjaro to Wegovy
Starting your switch from Mounjaro to Wegovy through EverydayMeds involves a streamlined three-step process designed for convenience and clinical safety. Begin with our 3-minute online clinical assessment, which captures your medical history, current medications including your Mounjaro experience, and weight management goals. Our prescriber review typically takes 3 working days (express 24-hour service available), during which your switching from Mounjaro to Wegovy plan is evaluated against current clinical guidelines. Once approved, next-day cold-chain delivery ensures your Wegovy arrives temperature-controlled and ready for use. The FlexTouch pen system is user-friendly, and detailed injection instructions are provided with every order. Our GPhC-registered pharmacy (#9012878) maintains strict quality standards throughout the switching from Mounjaro to Wegovy process.
Storage and Practical Considerations When Switching From Mounjaro to Wegovy
Wegovy requires refrigeration at 2-8°C before first use, but offers a practical advantage when switching from Mounjaro to Wegovy – it can be stored at room temperature (below 30°C) for up to 6 weeks once removed from the fridge, compared to Mounjaro's 21-day room temperature limit. This extended room temperature storage makes travel and daily use more convenient when switching from Mounjaro to Wegovy. The FlexTouch pen system is designed for once-weekly subcutaneous injection, typically in the thigh, upper arm, or abdomen. Each pen contains four doses of the same strength, lasting approximately one month. The mandatory dose escalation schedule cannot be accelerated, ensuring your body adjusts gradually when switching from Mounjaro to Wegovy. Always rotate injection sites and never share pens with others, as this is a prescription-only medicine requiring individual clinical oversight.
Cost Comparison and Long-Term Financial Planning When Switching From Mounjaro to Wegovy
When evaluating the financial commitment of switching from Mounjaro to Wegovy, consider both the escalation period costs and long-term maintenance expenses. The four-month escalation phase totals approximately £415 (using individual pen prices with discount codes), whilst annual maintenance costs at the 2.4mg dose amount to approximately £2,520 when switching from Mounjaro to Wegovy. This transparent pricing structure helps you budget effectively compared to variable NHS availability or unclear private prescription costs.
Our bundle options provide additional value when switching from Mounjaro to Wegovy, particularly the Intro Trio (0.25mg, 0.5mg & 1mg) at £299.99, covering your first three months. The Ultimate Stability Trio at £649.99 provides quarterly maintenance supply, reducing ordering frequency whilst maintaining competitive pricing. These bundles ensure uninterrupted treatment when switching from Mounjaro to Wegovy, avoiding potential supply gaps that could affect your weight management progress.
Making Your Switch: Next Steps for Moving From Mounjaro to Wegovy
Ready to begin switching from Mounjaro to Wegovy? Start with our comprehensive clinical assessment that captures your complete treatment history and switching rationale. Use code FIRST40 for new customer pricing, beginning at £79.99 for your starter dose. Our clinical team coordinates with your existing prescriber when necessary, ensuring continuity of care during your switching from Mounjaro to Wegovy journey. Remember that both medications must be used alongside a reduced-calorie diet and increased physical activity for optimal results. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment today, and join thousands of patients who've successfully made the switch with EverydayMeds' support. Returning customers can use code DOSE25 for ongoing competitive pricing throughout their treatment journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
